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Abstract Venous thromboembolism (VTE) is a common
event in cancer patients and one of the major causes of
cancer-associated mortality and a leading cause of mor-
bidity. In recent years, the incidence rates of VTE have
notably increased; however, VTE is still commonly
underestimated by oncologists. VTE is considered an
adverse prognostic factor in cancer patients in all settings.
In 2011 the Spanish Society of Medical Oncology (SEOM)
first published a clinical guideline of prophylaxis and
treatment of VTE in cancer patients. In an effort to
incorporate evidence obtained since the original publica-
tion, SEOM presents an update of the guideline for
thrombosis and cancer in order to improve the prevention
and management of VTE.
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Introduction
Venous thromboembolism (VTE) is a significant cause
of morbidity and death in patients with cancer. Although
deep vein thrombosis (DVT) of limbs and pulmonary
embolism (PE) are the most commonly encountered
venous thrombotic complications, other vascular terri-
tories, such as the splanchnic veins and central nervous
system can be involved. The risk of VTE is estimated to
be fourfold higher in cancer patients compared with
non-cancer patients. The true incidence of VTE in
cancer patients remains uncertain, with reported inci-
dence rates ranging from 0.8 % to over 30 % in some
populations, and depends on several factors (tumor, host
and treatment-related factors) [1]. VTE is often
asymptomatic or minimally symptomatic, therefore the
incidence is likely to be much higher. A steady increase
in the incidence of cancer-associated thrombosis (CAT)
has been observed in the past two decades due to
multiple factors: increasing age of general population
and cancer prevalence, improved imaging techniques
with enhanced detection of incidental thrombosis and
greater thrombogenicity of current multiagent chemo-
therapy regimens. Cancer patients with VTE have an
increased incidence of VTE recurrence and anticoagu-
lant-related bleeding complications compared with
patients without cancer. VTE has been found to be an
adverse prognosis factor in all stages of cancer [2]. In
the last decade it was postulated that the aggressiveness
of a malignant tumor is clearly correlated to the inci-
dence of VTE.
Here, we review the prophylaxis and treatment of VTE
in cancer patients using the GRADE system for all the
recommendations [3, 4].
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Risk factors
The risk of VTE varies notably between cancer patients,
even in the same patient over the course of the disease.
Risk factors for CAT can be divided into three categories:
patient-, treatment- and cancer- related factors (Table 1).
Prophylaxis
Prophylaxis of VTE in hospitalized medical cancer
patients
Hospitalization is one of the main VTE risk factors with sur-
gery and trauma. Medical hospitalized patients are at signifi-
cant risk of developing VTE and thromboprophylaxis has been
shown to be effective in three large randomized phase III trials
[5–7]. All three studies reported a significant reduction in VTE
following treatment with low-molecular-weight heparins
(LMWH) or fondaparinux, compared with placebo. However,
there is a lack of evidence regarding hospitalized cancer
patients, because no specific trials have ever been conducted in
the cancer population. The only evidence available is the
subgroup analysis of the aforementioned trials (Table 2).
LMWH trials showed similar VTE reductions; however, an
increase incidence of VTE paradoxically was observed with
fondaparinux. Major bleeding rates were not reported in the
three placebo-controlled trials. A recent meta-analysis [8] of
the cancer population in these three studies showed that cancer
patients did not gain a significant reduction in the incidence of
VTE when pharmacological anticoagulation was used. Dif-
ferent explanations have been suggested for this finding as lack
of statistical power, small number of patients included in the
analysis (307 patients), lack of stratification according to VTE
risk or cancer status, heterogeneity between studies, lack of
efficacy using standard doses of drug prophylaxis (higher doses
in this high-risk population) or low-risk patients included in
these trials. Finally, it has been suggested that fondaparinux is
less efficacious than LMWH.
Some observational studies suggest that VTE risk in can-
cer patients extends beyond their hospital stay; however, there
is no evidence to recommend extended thromboprophylaxis
after discharge. No specific trials have been performed with
the new oral anticoagulants (NOACS) in this setting in cancer
patients. To date there is a lack of validated risk assessment
tools for estimating the overall risk of VTE and bleeding in
hospitalized cancer patients. Identifying patients who could
benefit most from pharmacologic prophylaxis and performing
targeted thromboprophylaxis are important issues for spe-
cialists caring for cancer patients.
Table 1 Risk factors for VTE
Cancer-related
Site
Very high risk: pancreas, brain, stomach
High risk: lung, kidney, colon, uterus, bladder, testicular tumor
Low risk: prostate, breast
Stage/metastatic disease
Higher for metastatic disease over locally advanced or local
disease
Histology
Higher for adenocarcinoma over squamous cell carcinoma
Tumor grade
Higher for high-grade tumors (grade 3–4) compared to low
grade (grade 1–2)
Initial period after diagnosis (3–6 months)
Active disease























Comorbidities/medical problems (infection, pulmonary or renal




Low level of activity/physical exercise
Major trauma and immobilization
Inherited thrombophilia (Factor V Leiden)
BMI body mass index
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Recommendation
Despite the paucity of data, prophylactic anticoagulation
should be considered for hospitalized cancer patients with
acute medical illness in the absence of contraindications.
The preferred agents are LMWH (level of evidence: grade
1B). There is no evidence to recommend NOACS or
extended prophylaxis after hospital discharge.
Prophylaxis of VTE in surgical cancer patients
VTE is a common complication in cancer patients under-
going surgery. Cancer surgery doubles the risk of DVT and
the risk of fatal postoperative PE is four times higher
compared to similar procedures in the non-cancer popula-
tion. In addition, cancer surgery is associated with an
increased risk of bleeding. Several randomized studies and
meta-analyses have demonstrated the benefit of pharma-
cologic prophylaxis in this setting with LMWH and UFH
over no prophylaxis or placebo. Pharmacologic prophy-
laxis is ideally started before surgery or as soon as possible
in the postoperative period. Multiple trials in unselected
populations including cancer and non-cancer patients sug-
gest LMWH and UFH are equally effective. Due to similar
efficacy and unfavorable schedule (three times a day vs.
once a day), LMWH is preferable to UFH in surgical
cancer patients. There is a lack of data of the superiority of
one type of LMWH over another. Classically prophylaxis
is continued for at least 7–10 days. It must be noted 40 %
of the VTE events may occur later than 21 days from
surgical intervention [9]. Prolonged prophylaxis for up to
4 weeks must be considered in patients undergoing major
abdominal or pelvic surgery for cancer with additional risk
factors (Table 1) [10]. Mechanical methods of thrombo-
prophylaxis in monotherapy modestly reduce the frequency
of VTE in cancer patients. Few data are available from
prospective, randomized, controlled trials on their efficacy
in cancer patients. Pharmacological thromboprophylaxis is
superior to mechanical thromboprophylaxis in preventing
VTE [11]. So mechanical methods are commonly used as
an adjunct to pharmacological thromboprophylaxis. A very
important advantage of mechanical methods is they are not
associated to an increased risk of bleeding. The optimal
prophylaxis for laparoscopic surgery or minimally invasive
procedures has not been established and the real incidence
of VTE is not well known. The need for pneumoperito-
neum and reverse Trendelenburg position during laparo-
scopic procedure may increase the incidence of VTE in
these patients. Observational studies reported laparoscopic
surgery was associated with a lower incidence of VTE
compared to open surgery. A recent Italian study published
in 2013 showed the superiority of extended prophylaxis for
4 weeks over short prophylaxis (1 week) in patients who
underwent laparoscopic surgery for colorectal cancer.
Recommendation
In the absence of contraindications, all patients undergoing
major surgical intervention should receive pharmacologic
thromboprophylaxis (level of evidence: grade 1A). The
preferred agents are LMWH and prophylaxis should be
started before surgery or as soon as possible in the post-
operative period. Mechanical methods may be added to
pharmacologic prophylaxis in high-risk patients but should
not be used as monotherapy, unless pharmacologic pro-
phylaxis is contraindicated (level of evidence: grade 2C).
Patients should receive at least 7–10 days of prophylaxis
and patients undergoing major abdominal or pelvic cancer
surgery with high-risk features should be considered for
extended thromboprophylaxis for 4 weeks (level of evi-
dence: grade 1A).
We suggest the same recommendations for laparoscopic
surgery, risk factors and the duration and type of the pro-
cedure must be assessed (level of evidence: grade 2C).













ARTEMIS 849 15.4 Fondaparinux sc
(2.5 mg/24 h) vs.
placebo
5.6 vs. 10.5 %
p = 0.029
0.47 0.2 vs. 0.2 %
p = NS
20 17.0 vs. 3.9 % RR 4.3
NNH 8
MEDENOX 866 12.4 Enoxaparin sc
(40 mg/24 h) vs.
placebo
5.5 vs. 14.9 %
p \ 0.001
0.37 1.7 vs. 1.1 %
p = NS
11 9.7 vs. 19.5 % RR 0.50
(95 % CI 0.14–1.72)
NNT 10
PREVENT 3,706 5.1 Dalteparin sc
(5,000 UI/24 h) vs.
placebo
2.8 vs. 5.0 %
p = 0.0015
0.55 0.5 vs. 0.2 %
p = NS
45 3.1 vs. 8.3 % RR 0.37
NNT 18
sc subcutaneously, VTE venous thromboembolism, NS not significant, NTT number of patients needed to treat to avoid one event, NNH number
needed to harm, RR relative risk, CI confidence interval
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Prophylaxis of VTE in ambulatory cancer patients
during chemotherapy
Chemotherapy has been identified as an independent risk
factor for VTE. The rates of thrombosis in ambulatory
patients receiving chemotherapy vary widely and depend
on multiple factors (see Table 1). Several randomized trials
evaluating ambulatory prophylaxis with LMWH and low-
dose warfarin in ambulatory cancer patients have been
published with inconsistent results largely due to the het-
erogeneity of the populations studied and the treatments
used (duration, drugs, dose, etc.). Since 2009 four ran-
domized trials [12–15] and three meta-analyses [16–18]
have been published and have changed the landscape of
thromboprophylaxis in this setting (Table 3). All studies
randomized patients with cancer receiving chemotherapy
to venous thromboprophylaxis or placebo. These studies
consistently demonstrate the benefit of thromboprophylaxis
in different types of malignancies with a significant
reduced risk of VTE with an acceptable safety profile.
However, the overall rates of VTE among patients assigned
to placebo were very low, ranging 3–4 % in the multi-
tumor trials which is lower than observed in the real world
[12, 13]. The lower VTE incidence rates have been sug-
gested by the inclusion of selected low-risk patients.
Therefore, despite a consistent and robust reduction in the
risk of VTE with a hazard ratio under 0.4 in these studies,
the difference in absolute risk is small. The rate of major
and minor bleeding was similar between the two arms.
Even though there was a decrease in the VTE incidence no
difference in overall survival was observed. The effect of
this type of thromboprophylaxis on quality of life has not
been assessed. According to the evidence from these trials
and Cochrane meta-analysis the number of patients needed
to treat to avoid one VTE event (NNT) would range
between 46 and 60. In consequence, all these issues and the
cost of LMWH have limited the expansion of thrombo-
prophylaxis in the ambulatory setting. A pooled analysis
Table 3 Prophylaxis of VTE in ambulatory cancer patients during chemotherapy: recentclinical trials and meta-analysis
Study Number
of patients
Type of tumor Risk of thrombosis LMWH Dose
PROTECHT
Lancet Onc’09
1,150 Lung, pancreas, stomach,
colorectal, breast,
ovarian, head and neck
cancer
High (pancreas, stomach)
Low (breast, head and neck)
Nadroparin 3,800 UI/24 h
FRAGEM UK
EJC’11
123 Pancreas High Dalteparin 200 UI/kg/24 h 9 4 weeks
followed 150 UI/kg/
24 h 9 8 weeks
CONKO 004
ASCO’10
312 Pancreas High Enoxaparin 1 mg/kg/24 h 9 3 m,
followed
40 mg/24 h 9 3 m
SAVE ONCO
NEJM’12
3,212 Lung, colorectal, stomach,
pancreas, kidney and
ovarian cancer
Moderate–high Semuloparin 20 mg/24 h
Meta-analysis
Cochrane 2012
3,538 Multiple neoplasms Not defined – –
Akl pooled analysis
NEJM’12
&6.000 Multiple neoplasms Not defined – –
Duration VTE (%) CT ? LMWH vs. CT Major bleeding CT
? LMWH vs. QT
Minor bleeding CT
? LMWH vs. CT
NNT
4 months 2.0 vs. 3.9 % *(VTE ? ATE) p = 0.02 0.7 vs. 0 % p = 0.18 7.4 vs. 7.9 % 53
12 weeks 3.4 vs. 23.0 % RR 0.145, p = 0.002 3.4 vs. 3.2 % 9.0 vs. 3.0 % –
6 months 5.1 vs. 15.6 % p \ 0.05 No difference p = NS NR 12 (sVTE)
Until a change of CT regimen 1.2 % vs. 3.4 % HR 0.36, p \ 0.001 1.2 vs. 1.2 % 1.6 vs. 0.9 % 46
– Heparin vs. no prophylaxis 60 (sVTE)
0.55 (0.34–0.88) 1.57 (0.69–3.60) –
– Heparin vs. no prophylaxis –
0.57 (0.40–0.81) 1.06 (0.71–1.57) 1.18 (0.89–1.55)
m months, mg milligram, CT chemotherapy, NNT number of patients needed to treat to avoid one event, sVTE symptomatic venous throm-
boembolism, NS not significant, HR hazard ratio
* Venous thromboembolism incidence plus arterial thormboembolism incidence
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[18] that included more than 6,000 patients showed a sig-
nificant reduction in symptomatic VTE (relative risk 0.57,
95 % CI 0.40–0.81) and a non-significant effect on major
or minor bleeding (Table 3). This analysis also suggested a
small survival benefit for prophylaxis with LMWH (rela-
tive risk 0.94, 95 % CI 0.88–1.00) not observed in the
previous studies [18].
The risk of VTE in patients diagnosed with multiple
myeloma receiving treatment with thalidomide or lenalid-
omide plus chemotherapy or dexamethasone ranges from
12 to 28 %. When any pharmacologic thromboprophylaxis
strategy is scheduled, this figure drops below 10 %. There
is a lack of randomized studies in patients with multiple
myeloma treated with thalidomide or lenalidomide in
combination with chemotherapy or dexamethasone com-
paring VTE prophylaxis vs. observation. Two randomized
controlled trials that compared different strategies of pro-
phylaxis have been published [19, 20]. They showed
aspirin and LMWH are acceptable thromboprophylaxis
options and both suggested slightly greater efficacy of
LMWH compared with aspirin.
It is important to identify patients at higher risk for
whom prophylaxis may be beneficial. A validated risk
assessment model (RAM) for identifying patients at high
risk for VTE receiving chemotherapy has been validated by
Khorana et al. [21]. Five predictive variables were identi-
fied and three different risk categories were defined
(Table 4). This RAM is also highly predictive of mortality
and progression-free survival. Recently, this model has
been expanded with the addition of D-dimer and P-selectin.
The addition of these biomarkers improves the risk pre-
diction of VTE considerably; nevertheless, this expanded
model has little impact since P-selectin is not available in
clinical practice and has not been validated. In the near
future new biomarkers may enhance the VTE prediction in
this setting.
Recommendation
Routine thromboprophylaxis is not recommended in
ambulatory cancer patients receiving chemotherapy (level
of evidence: grade 1B). LMWH may be considered in high-
risk ambulatory cancer patients, as advanced pancreatic
cancer or patients with a Khorana score C3, with low
bleeding risk. Ambulatory patients who are receiving
chemotherapy and prophylaxis with LMWH against VTE
should be closely monitored.
It is recommended to assess the risk of VTE in all
patients starting chemotherapy. Khorana’s score is the only
validated RAM in cancer patients receiving chemotherapy
and is the recommended tool to assess VTE risk. Risk
assessments should be performed periodically throughout
the patient’s chemotherapy (level of evidence: grade 2C).
Pharmacologic thromboprophylaxis is recommended in
patients diagnosed with multiple myeloma receiving
treatment with thalidomide or lenalidomide plus chemo-
therapy or dexamethasone. LMWH is recommended for
high-risk patients and aspirin for low-risk patients (level of
evidence: grade 2B).
Prophylaxis of VTE in cancer patients with central
venous catheters
Central venous catheters (CVC) are associated with
upper extremity DVT and PE and are considered inde-
pendent risk factors for VTE. Controversy remains
regarding the true incidence of the disease, as many
CVC-associated VTEs remain subclinical. The latest data
suggest that while CVC-associated symptomatic VTE
incidence only amounts to 2–5 %, asymptomatic VTE
may be as high as 27–66 %, depending on the screening
method used. In recent years a reduction of the CVC-
associated VTE rate has been described. This finding is
likely to be due to the introduction of less thrombogenic
materials in the manufacturing of CVC. The most recent
and largest studies and a meta-analysis of randomized
trials did not show clinically meaningful degrees of
protection against catheter-induced upper extremity
venous thrombosis using either low-dose warfarin or
LMWH in patients with cancer. Several studies including
one meta-analysis [22] have suggested that CVC should
be placed on the right side, in the jugular vein and the
catheter tip should be positioned at the right atrium/
superior vena cava junction.
Table 4 Khorana’s risk assessment model (RAM)
Patient characteristics Risk score points
Site of cancer
Very high risk (stomach, pancreas) 2
High risk (lung, lymphoma, gynecologic,
genitourinary excluding prostate)
1
Pre-chemotherapy platelet count C350,000/mm3 1
Hemoglobin level less than\10 g/dl or use of red
cell growth factors
1
Pre-chemotherapy leukocyte count[11,000/mm3 1
BMI 35 C 35 kg/m2 1





BMI body mass index, sVTE symptomatic VTE
Clin Transl Oncol (2014) 16:1079–1090 1083
123
Recommendation
Routine prophylaxis of VTE in cancer patients with CVC is
not recommended. To reduce the incidence of VTE, CVC
should be placed on the right side, in the jugular vein and
the catheter tip should be positioned at the right atrium/
superior vena cava junction (level of evidence: grade 1A).
Treatment
The goals of anticoagulant therapy in cancer patients with
CAT are to improve symptoms, reduce risk of recurrent
VTE and decrease the risk of post-thrombotic syndrome
(PTS). Anticoagulation is the cornerstone of treatment.
Cancer patients present a higher risk of recurrent VTE and
anticoagulant treatment-related bleeding compared to those
without malignancy during anticoagulation therapy [23].
Initial treatment of VTE in cancer patients (5–10 days)
There are no randomized trials to specifically assess the
initial treatment of VTE in cancer patients. Available
clinical evidence comes from subgroup analysis and a
meta-analysis of 16 randomized studies developed in the
general population [24]. These studies neither found no
significant differences in the VTE recurrence rate between
LMWH and UFH nor the incidence of bleeding. However,
a significant reduction in mortality at 3 months in favor of
LMWH compared with UFH (RR 0.71 CI 95 % 0.52–0.98)
was shown. Initial treatment (5–10 days) of CAT with
LMWH at a body weight-adjusted dose has become the
drug of choice. LMWH administered subcutaneously is at
least as safe and effective as UFH administered intrave-
nously and LMWH usually requires no laboratory moni-
toring. Moreover, LMWH is associated with a reduced risk
of developing heparin-induced thrombocytopenia (HIT)
and osteoporosis compared to UFH. Alternative agents are
UFH and fondaparinux according to the patient’s charac-
teristics and clinical situation. Fondaparinux is similar to
LMWH in terms of administration route, efficacy, costs
and convenience, but available data from randomized trials
about this drug in cancer patients are scarce, so its use must
be restricted to avoid HIT and previous allergic reactions to
heparins.
Due to the lack of data in cancer populations, the indi-
cations and contraindications for the initial use of throm-
bolytic therapy are essentially the same as for non-cancer
patients. The indications and potential benefits must be
carefully weighed against the risk of adverse effects for
each patient, due to the higher risk of major and fatal
bleeding. Generally, it is only advisable in the management
of patients with life- or limb-threatening thrombotic events.
Multiple thrombolytic agents and regimens have been used,
but any superiority of a particular agent or regimen remains
to be definitively established.
Recommendation
LMWH at a body weight-adjusted dose is the drug of
choice for the initial treatment of CAT (level of evidence:
grade 1A). Thrombolytic therapy is only recommended in
patients with life- or limb-threatening thrombotic events
(level of evidence: grade 2C).
Treatment of central venous catheter-associated
thrombosis (CVCAT)
The cornerstone of the treatment of CVCAT is anticoag-
ulant therapy and anticoagulation without CVC removal is
the preferred approach in this setting. The type, duration
and intensity of anticoagulant therapy of upper extremity
deep vein thrombosis (UEDVT) should be the same as in
the strategy employed for DVT of the legs. It is recom-
mended to remove the CVC if [25, 26]: the catheter is not
functional or the catheter is no longer needed, failure of
anticoagulation therapy is observed, anticoagulation is
contraindicated or in catheter infection. Anticoagulation
should continue for as long as the catheter is in place and
for at least 3 months after catheter removal. For massive
CVC-associated UEDVT and PE, thrombolytic therapy
must be considered.
Recommendation
The treatment strategy of CVCAT should be the same as
recommended in the treatment of DVT of the lower limbs
(level of evidence: grade 2C).
Treatment of acute PE
The clinical spectrum of PE ranges from an acute life-
threatening event to a silent finding in scheduled CT scans.
The strongest predictor for short-term PE-related mortality
is hemodynamic status. In patients with hemodynamic
instability the short-term mortality rate ranges from 15 to
60 % of cases and acute thrombolytic therapy should be
considered in this setting after weighting the PE severity
and the risk of bleeding. The use of the catheter or surgical
embolectomy may also be considered in patients with
massive PE with contraindications to thrombolytic therapy
or in those that remain unstable after thrombolysis. How-
ever, the vast majority of patients with PE are hemody-
namically stable at diagnosis. Anticoagulation with
1084 Clin Transl Oncol (2014) 16:1079–1090
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LMWH is currently the treatment of choice in patients with
normotensive PE even in those with right ventricular dys-
function according to data from recent trials which have
failed to demonstrate that the benefits of systemic throm-
bolysis outweigh the risk of bleeding in this setting. Several
risk-stratification tools that include clinical decision rules,
cardiac biomarkers or imaging tests have been developed
to classify patients with normotensive PE. Of note, since
cancer has been found to be an independent predictor of
death in series of patients with acute symptomatic PE,
general PE prognostic scales include cancer as a predictive
variable limiting its use in the cancer population. This fact
has led to the development of specific prognostic scales for
acute symptomatic cancer-related PE including the
POMPE-C tool [27] and a score derived from the Riete
registry [28].
Recommendation
LMWH is the treatment of choice in patients with PE (level
of evidence: grade 1A).
Treatment of incidental PE
It is known that subclinical or asymptomatic PE may be
present in up to 50 % of patients with acute DVT. Incidental
or unsuspected VTE found during the evaluation of sched-
uled CT scan evaluations in cancer patients is common,
accounting for 2–5 % of all CT scans. Incidental PE cur-
rently represents about 50 % of PE burden in cancer
patients. Moreover, the incidence of incidental VTE is likely
to increase further with the improvements of imaging
techniques. Limited data from retrospective and observa-
tional cohorts of patients suggest that patients with inci-
dental VTE would have similar outcomes with regard to
overall survival and the risk of bleeding and VTE recurrence
compared to patients with acute symptomatic events [29].
Unfortunately, there is a lack of evidence from prospective
interventional studies to assess the best management of
incidental VTE and whether anticoagulation is indicated or
beneficial in patients with incidental VTE remains contro-
versial. Expert recommendations suggested treating inci-
dental VTE with standard full-dose anticoagulation therapy
similarly to symptomatic events. However, in cases where
the diagnosis of VTE is doubtful or questionable such as in
cases of isolated subsegmental PE, additional confirming
tests such as compression venous ultrasonography or CT
scan pulmonary angiography should be performed.
Recommendation
Anticoagulation therapy is considered the standard treat-
ment of incidental PE (level of evidence: grade 1C).
Long-term treatment of CAT
The preferred agent for long-term management and sec-
ondary VTE prophylaxis (from first 5–10 days up to
3–6 months after the VTE diagnosis) in cancer patients is
LMWH. This recommendation is based on several ran-
domized controlled trials [30–33] and a meta-analysis of 7
studies [34] which have provided consistent evidence on
improved efficacy of LMWH (dalteparin, enoxaparin and
tinzaparin) compared to vitamin K (VKA) antagonists in
this setting (Table 5). Overall, a relative risk reduction of
53 % in the prevention of recurrent VTE has been observed
with the use of LMWH compared to VKA with similar
rates of major bleeding and overall mortality. A post hoc
analysis of CLOT trial [35] showed that treatment with
dalteparin was associated with improved overall survival in
patients without metastatic disease (probability of death at
12 months: 20 % in the dalteparin group vs. 36 % in the
VKA arm, HR 0.50; 95 % CI 0.27–0.95; p = 0.03) com-
pared to AVK treatment. In the largest one of these trials,
the CLOT study, dalteparin was administered at a full dose
for the first month followed by a 25 % reduction in the
treatment dose for the remaining 5 months. This LMWH
dose reduction approach can be considered especially in
patients with previous history of bleeding or with a higher
risk of bleeding. LMWH offers additional advantages
compared to VKA in the long-term management of cancer-
related VTE: limited drug interaction and a shorter half-life
that facilitates temporary interruption for invasive proce-
dures or thrombocytopenia.
Unfortunately, trials addressed to test the risk/benefit of
extended duration of anticoagulation beyond 6 months are
not available. Individualized decisions to tailor therapy
according to the characteristics and preferences of each
patient are challenging in clinical practice. Specific tools
aimed to ‘predict VTE recurrence’ have been developed in
recent years which may provide further support to clini-
cians in the decision to maintain extended anticoagulation
beyond 6 months. Four risk assessment models combining
clinical and biomarker variables are currently available to
predict VTE recurrence, of which only one was specifically
designed to predict recurrence in cancer patients known as
Ottawa score [36] (Table 6).
Recommendation
The preferred agent for long-term anticoagulant treatment
of VTE in cancer patients is LMWH for at least 6 months
(level of evidence: grade 1A). Extended duration of anti-
coagulation therapy after 6 months should be considered
for high-risk patients such as those with active cancer and
those receiving chemotherapy. Beyond 6 months, patients
should be re-evaluated frequently to assess the risk–benefit
Clin Transl Oncol (2014) 16:1079–1090 1085
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ratio of continuing anticoagulant therapy (level of evi-
dence: grade 2C).
Special situations in the management of cancer-
associated VTE
Treatment of recurrent VTE during anticoagulation
therapy
The reported rates of recurrent VTE during anticoagulant
therapy in clinical trials are 7–10.5 % in patients treated
with LMWH (Table 5). Gender, tumor type, TNM staging
and prior history of VTE have been found to be risk factors
for VTE recurrence in cancer patients. Cancer progression
should also be considered in patients with recurrent VTE.
Despite the high frequency and relevance of recurrent VTE
in clinical practice, there is a lack of evidence to guide its
management. An empirical approach for the management of
recurrent VTE is proposed (Fig. 1). HIT in patients who
were first exposed to LMWH or UFH, non-compliance and
sub-therapeutic anticoagulant doses have to be ruled out and
adjusted. If recurrent VTE occurs while receiving thera-
peutic anticoagulation VKA doses, it is recommended VKA
be switched to LMWH. In patients who experience VTE
recurrence despite therapeutic weight-adjusted LMWH, it is
recommended to continue LMWH at a higher dose starting
with an LMWH dose escalation by 20–25 %. If another VTE
episode occurs after the first dose escalation, further dose
increase or twice-daily dosing of LMWH is considered to be
reasonable option. The use of peak anti-activated factor X
(anti-factor Xa) levels may help to estimate further tailor
LMWH escalation, although published evidence to support
this strategy is lacking. The insertion of an inferior vena cava
(IVC) filter in addition to anticoagulation is not currently
recommended in preventing recurrent thrombosis. Data on
the efficacy and safety of IVC filters in cancer patients are
limited to retrospective single-center series and anecdotal
reports. Available data from the PREPIC trial shows that
IVC filter reduced the risk of PE but increased that of DVT
and had no impact on patient survival [37]. Therefore, the
use of IVC filters should be considered only in patients who
cannot received anticoagulation or recurrent VTE occurs
despite adequate anticoagulant therapy management,
although evidence from prospective data are not available.
Recommendation
If recurrent VTE occurs with therapeutic weight-adjusted
doses, a dose escalation could be performed (level of evi-
dence: grade 2C).
IVC must be considered when anticoagulation is con-
traindicated or recurrent PE occurs despite adequate anti-
coagulant management (failure of anticoagulation). It is
recommended to associate anticoagulation therapy to IVC,
in those cases in which anticoagulation is contraindicated,
it should be resumed as soon as possible (level of evidence:
grade 2C).
Thrombocytopenia
The optimal dosing of LMWH in the thrombocytopenic
patient has not been properly investigated in clinical trials.
The recommended approach by expert consensus is to
maintain full-dose anticoagulation for platelet count
[50 9 109/L. For platelet counts between 20 and
Table 5 Randomized trials comparing LMWH with AVK for cancer-related VTE secondary prophylaxis
Clinical trial/
year








CLOT 2003 Dalteparin 25 % LMWH dose
reduction after 1 month




Enoxaparin full dose once daily 146 3 months 21.1 vs. 10.5 %;
p = 0.09




Enoxaparin 2 full-dose schemes
(twice and once daily)a
122 6 months 10 vs. 6.9 vs. 6.3. %;
p = NS
2.9 vs. 6.5 vs.
11.1 %; p = NS
32.4 vs. 22.6 vs.
41.7 %; p = NS
LITE 2006 Tinzaparin full dose 200 3 months 16 vs, 7 %;
p = 0.044
7 vs. 7 %; p = NS 19 vs. 20 %;
p = NS
a AVK vs. enoxaparin 1 mg/KG/12 h and AVK vs. enoxaparin 1.5 mg/kg/day
Table 6 Risk assessment model for cancer-associated recurrent





TNM stage I -2
Prior VTE ?1
-3 to 0 points: low VTE recurrence probability (B4.5 % VTE
recurrent risk)
1 to 3 points: high VTE recurrence probability ([19 % VTE recurrent
risk)
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50 9 109/L, half-dose or prophylaxis dose of LMWH and
close monitoring. And for platelet count\20 9 109/L, it is
recommended to hold anticoagulation. In the acute period
after VTE (first month), the risk of recurrent VTE is higher
and platelet transfusion to maintain platelet counts
[50 9 109 should be considered to allow maintaining a
full-dose anticoagulant treatment.
Anticoagulation in special situations: obesity, renal
impairment and elderly
LMWH must be used with caution in obese and elderly
patients and in those with renal insufficiency. Due to their
predominantly renal elimination, LMWH accumulation is
expected with long-term use in those with creatinine
clearance\30 mL/min. Obese patients and elderly patients
have a lower proportion of lean body mass as a percentage
of total body weight. As a result, LMWH dosing based on
total body weight could cause supra-therapeutic anticoag-
ulation. LMWH appropriate dosing in patients with severe
renal impairment (CrCl \ 30 mL/min) is uncertain and
must be cautiously used with regular monitoring of renal
function and anti-Xa levels with dosage adjustment. UFH
and AVK therapy are not reliant on renal elimination and
are considered to be an alternative approach in this setting
for long-term treatment according to expert recommenda-
tions if anti-factor Xa is not available.
Anticoagulation and central nervous system
malignancies
VTE is common perioperatively and through the course of
brain tumor therapy with an incidence of 20–30 % per year




Fig. 1 Management of
recurrent cancer-associated
thrombosis (CAT)
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serious and life-threatening intracranial bleeding. No ran-
domized controlled trials exist to evaluate the best man-
agement of VTE in patients with primary or metastatic
intracranial tumors. Nonetheless, small retrospective stud-
ies indicate that anticoagulation can be safely used in this
challenging setting and therefore standard anticoagulation
is recommended in these patients.
Management of splanchnic vein thrombosis
Splanchnic vein thrombosis (SVT), involving the portal,
splenic, mesenteric, or hepatic veins is a common event in
cancer patients. Treatment of SVT is a clinical challenge due
to heterogeneity of clinical presentations, increased bleeding
risk, and lack of evidence from clinical trials. In recent years,
different advances in diagnostic imaging techniques have led
to an increase in the diagnosis of incidental SVT. Patients
with acute, symptomatic SVT with low risk of bleeding
should be treated with anticoagulation therapy. For patients
with asymptomatic incidentally detected SVT, there is no
specific guidance on treatment. It is reasonable to withhold
anticoagulation if the patient is truly asymptomatic, espe-
cially if radiologic evidence indicates that the thrombus is
chronic. Closely monitoring imaging is recommended to
detect thrombus progression if anticoagulation is not given.
Recommendation
Acute symptomatic SVT should be treated with anticoag-
ulant therapy. Treatment of asymptomatic incidentally
detected SVT should be individualized in every patient
(level of evidence: grade 2C).
Prevention of PTS
PTS is a frequent complication (20–50 %) within the first
2 years after DVT and is a common cause of morbidity.
Clinical manifestations are usually leg pain, edema, swell-
ing and eczematous skin changes which may range from
mild complaints to intense pain intervening with daily
activities. The only method that has been shown to be
potentially effective in the prevention of PTS is the use of
graduated compression stockings. Previous small and non-
placebo trials suggest a benefit of elastic compression
stockings (ECS) to prevent PTS with an overall reduction of
50 % in severe PTS. A recent study published in 2014 (SOX
trial) [38] randomized patients to ECS used for 2 years or
placebo after a first proximal DVT. The incidence of PTS
was 14.2 % in the experimental arm vs. 12.7 % in the
placebo group (HR 1.13, 95 % CI 0.73–1.76; p = 0.58).
The findings of the SOX trial do not support routine wearing
of ECS after DVT for the prevention of PTS.
Recommendation
ECS is not recommended routinely to prevent PTS (level of
evidence: grade 1B).
VTE: Antiangiogenic therapy/anti-epidermal growth
factor receptor (EFGR) therapy
Venous or arterial thromboembolism and bleeding are
adverse events linked to angiogenesis inhibitors. Combi-
nation treatment with bevacizumab and chemotherapy
compared with chemotherapy alone was associated with a
modest but significant twofold increased risk of arterial
thromboembolic disease (ATD), but the impact on the risk
of VTE remains controversial [39, 40]. Development of
ATD with bevacizumab treatment was associated with a
prior arterial thromboembolic event in patients older than
65 years. The prophylactic use of acetylsalicylic acid is
controversial. The start of treatment with bevacizumab
after an ATD must be individualized, but the minimum
interval recommended is 6 months. If an ATD takes place
during treatment with bevacizumab, its use must be stop-
ped permanently because the safety of resuming bev-
acizumab has not been studied. In patients who develop
VTE during bevacizumab treatment, the minimum safety
interval recommended to resume bevacizumab is 2 weeks
with stable dose of anticoagulant treatment. If there is a
grade 4 VTE episode during treatment with bevacizumab,
its use must be permanently stopped. Recommendations
regarding aflibercept (an anti-VEGF recombinant fusion
protein) are similar to those with bevacizumab.
VEGF tyrosine kinase inhibitors (TKI) are used in
multiple cancers. In a meta-analysis evaluating the risk of
ATD associated with sunitinib and sorafenib, a significant
threefold increase was observed [41]. These results may be
related to the higher time exposure to sunitinib and so-
rafenib in the trials as confounding factor.
A meta-analysis that explored the risk of VTE with anti-
EGFR drugs (either monoclonal antibodies-MoAbs- or
TKIs) showed that anti-EFGR therapy increased by 32 %
the risk of VTEs, but not of ATEs. This thrombotic risk is
increased with cetuximab and panitumumab but not with
gefitinib and erlotinib. The differences in the results
between MoAbs and oral TKIs are still unknown, but the
association of cetuximab and panitumumab with other
cytotoxic agents probably matters [42].
Anticoagulation in the absence of VTE to improve
survival in cancer patients
The mechanism by which anticoagulation might provide a
survival benefit beyond the prevention of VTE is unknown.
Several clinical trials have tested anticoagulant therapy in
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cancer patients without VTE with survival as primary end
point with inconclusive results [43–46]. The survival ben-
efit may be dependent on the tumor and the extent of dis-
ease, being larger with localized disease and small-cell
lung cancer.
Recommendation
Currently anticoagulant therapy in cancer patients without
VTE with the intention to improve survival cannot be
recommended (level of evidence: grade 1B).
New oral anticoagulants and VTE in cancer patients
There are three (NOACs) currently marketed in Spain,
dabigatran etexilate (direct thrombin inhibitor), rivarox-
aban and apixaban (factor Xa inhibitors). NOACs have
been studied in large randomized clinical trials for acute
VTE treatment and for VTE prophylaxis. In these trials, the
number of patients with active cancer enrolled was small.
Due to the paucity of data in the oncology subgroup, the
results of these trials cannot be generalized to cancer
patients, and additional information is needed about the
efficacy and safety of NOACs in this population. There is
an additional concern about the drug interactions between
NOACs and either chemotherapy or biological treatments.
Recommendation
NOACS are not recommended for the treatment of VTE in
cancer patients (level of evidence: grade 1B).
Anti-Xa monitoring
The determination of anti-Xa in blood is the method of
choice for monitoring the therapeutic range of LMWH.
Anti-Xa monitoring is not routinely recommended in
LMWH treatment. There is only one randomized trial that
compares adjusted vs. fixed doses of LMWH in the treat-
ment of DVT. Treatment efficacy and hemorrhagic com-
plications did not differ between the two groups [47]. In
special populations like obese, renally impaired, elderly,
thrombocytopenic or patients with high risk of bleeding
anti-Xa is currently recommended.
Recommendation
Anti-Xa monitoring is not routinely recommended in
LMWH treatment (level of evidence: grade 1B).
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